Door Pharma

Door Pharma is a private discovery-stage biotech focused on antiviral drug discovery against virus structural proteins. The company was founded in 2018 by Indiana University HBV researcher Adam Zlotnick and is building small-molecule approaches designed to disrupt viral assembly and other structural protein functions. Its lead scientific focus appears to be hepatitis B virus core protein modulators, including approaches complementary to Assembly Biosciences' HBV portfolio. Door presents itself as a platform company whose technologies may be applicable across multiple viruses, with work spanning chemical biology, structural biology, and virology. The company remains at an early stage with no disclosed commercial products or late-stage clinical assets.